BPC-157 vs Cartalax
Extensively Studied vs Emerging
compatible Different mechanisms; no direct interaction.
Molecular Data
BPC-157 Cartalax
Weight 1,419.53 Da ~350 Da
Half-life <30 minutes Minutes (short peptide); effects persist via epigenetic changes
Chain 15 amino acids 3 amino acids
Type Pentadecapeptide Tripeptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Cartalax
01 Joint and connective tissue support
02 Potential anti-aging effects on fibroblasts
03 Cartilage regeneration support
04 Established safety profile in Russian clinical practice
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Cartalax
100-200mcg oral (1-2 capsules) or 700-1400mcg injectable / 1-2 times daily with meals (oral) or once daily (injectable)
Tissue Regeneration 700-1400mcg (10-20mcg/kg) Daily
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Cartalax
No reported side effects in Russian clinical use when taken properly
Well-tolerated in elderly patients
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Pregnancy and breastfeeding
Active cancer (theoretical proliferation risk)
Research Evidence
BPC-157 Cartalax
Status Extensively Studied Emerging
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.